Seronegative and seropositive RA: Alike but different?

Nature Reviews Rheumatology

Volumn 11, Issue 1, 2015, Pages 8-9

  Ajeganova, Sofia ^a   Huizinga, Tom W J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; RHEUMATOID FACTOR;

CANADA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; HUMAN; JOINT RADIOGRAPHY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; SHORT SURVEY; TIME TO TREATMENT; TREATMENT INDICATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CANADA; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 84926407372     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.194     Document Type: Short Survey

References (10)

1. Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144-152 (2012).
2. Barra, L. et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J. Rheumatol. http://dx.doi.org/10.3899/jrheum.140082.
3. De Punder, Y. M. et al. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. J. Rheumatol. 40, 1268-1274 (2013).
4. Van den Broek, M. et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann. Rheum. Dis. 71, 245-248 (2012).
5. Van der Woude, D. et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford) 51, 1120-1128 (2012).
6. Seegobin, S. D. et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res. Ther. 16, R13 (2014).
7. Wevers-de Boer, K. et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann. Rheum. Dis. 71, 1472-1477 (2012).
8. De Rooy, D. P., Willemze, A., Mertens, B., Huizinga, T. W. & Van der Helm-van Mil, A. H. Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res. Ther. 13, R180 (2011).
9. Trouw, L. A., Huizinga, T. W. & Toes, R. E. Autoimmunity in rheumatoid arthritis: different antigens - common principles. Ann. Rheum. Dis. 72 (Suppl. 2), ii132-ii136 (2013).
10. Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372-17377 (2011).